Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301878 | 0.74 | ABCB1 (0.55) | KDM4CLMNAHTTNPC1RAB9A | |
| SCHEMBL8883561 | 0.72 | LMNA (0.60) | KDM4CLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL1779819 | 0.71 | HTT (0.64) | KDM4CLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL27458708 | 0.71 | ALDH1A1 (0.50) | KDM4CLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL3835167 | 0.69 | HTT (0.64) | KDM4CLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL29956682 | 0.69 | LMNA (0.60) | KDM4CLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL1267498 | 0.69 | SMN1; SMN2 (0.66) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8883850 | 0.69 | LMNA (0.60) | KDM4CLMNAHTTSMN1; SMN2RAB9A | |
| Acetic Acid SCHEMBL9593918 | 0.69 | LMNA (0.56) | KDM4CLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL5752394 | 0.68 | MPO (0.51) | KDM4CLMNAHTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | claimed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | claimed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | claimed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | claimed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3094619-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| WO-2015106240-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106240-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HIF1AN, HBG2, HIF1A | KDM4C 2688/4885LMNA 4829/4885HTT 1252/4885 |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | HIF1AN, HBG2, HIF1A | KDM4C 2688/4885LMNA 4829/4885HTT 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.